Pharmaceutical

AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data

Participants cannot remain blind to their treatment arm due to the properties of TauRx's drug, which causes urinary discoloration.

Mar 9, 2024 - 18:00
AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data
Participants cannot remain blind to their treatment arm due to the properties of TauRx's drug, which causes urinary discoloration.
Read the original article

Tags:

Previous Article

STAT+: Former medical device CEO who sold dummy, plastic parts convicted of fraud

Next Article

AD/PD 2024: exploring cutting-edge therapies for ALS

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Twist Bioscience and Astellas team up for antibody discovery

Twist Bioscience and Astellas team up for antibody disc...

Apr 22, 2023

STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts

STAT+: Pharmalittle: Biotech investors push to extend t...

Oct 18, 2023

STAT+: FDA approves Seres microbiome drug, as field advances

STAT+: FDA approves Seres microbiome drug, as field adv...

Apr 27, 2023